ArticleCell2022
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.
Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.Nature medicine · 2024Trial
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.Frontiers in immunology · 2022Trial
- Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity.NPJ vaccines · 2026Article
- CD8Nature · 2026Article
- Conformational bias in SARS-CoV-2 Spike CD4+ T-cell epitope dominance.Frontiers in immunology · 2026Article
- Structural insights into clonal restriction and diversity in T cell recognition of two immunodominant SARS-CoV-2 nucleocapsid epitopes.Nature communications · 2025Article
- Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19.NPJ vaccines · 2025Article
- A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.NPJ vaccines · 2025Article
- A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2.NPJ vaccines · 2024Article
- SARS-CoV-2-Specific T-Cell as a Potent Therapeutic Strategy against Immune Evasion of Emerging COVID-19 Variants.International journal of molecular sciences · 2024Article
- mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer.Journal for immunotherapy of cancer · 2024Article
- Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant.Nature communications · 2023Article
- SARS-CoV-2 infection establishes a stable and age-independent CD8Nature communications · 2023Article
- Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDNPJ vaccines · 2023Article
- An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.Nature communications · 2023Article
- Impact of SARS-CoV-2 exposure history on the T cell and IgG response.Cell reports. Medicine · 2023Article
- Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine.Frontiers in immunology · 2023Article
- A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses.Immunotherapy advances · 2023Article
- Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice.iScience · 2022Article
- Differential peripheral blood mononuclear cell reactivity against SARS-CoV-2 proteins in naïve and previously infected subjects following COVID-19 vaccination.Clinical immunology communications · 2022Article
Corrections and comments
- Erratum for
Authors and funding
20 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.